{"version":"1.0","type":"link","title":"Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.","author_name":"Tsurutani J 외","author_url":"https://prs-insight.online/author/Tsurutani%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/78463","thumbnail_width":1200,"thumbnail_height":630}